IGC, Inc. (India Globalization Capital, Inc.) — Form 10-Q
Reporting period: Quarter and nine months ended December 31, 2022 (the company’s fiscal third quarter and nine-month period). Amounts below are in U.S. dollars; financial statement amounts are in thousands unless otherwise noted.
Business context
The company develops investigational treatments, including IGC-AD1, in a Phase 2B trial for agitation associated with Alzheimer’s dementia, and TGR-63, in preclinical development. It also sells wellness products and provides white-label services through its Life Sciences segment. Its legacy Infrastructure segment performs construction work and rents heavy equipment in India.
Financial results and liquidity
| Metric | Three months ended Dec. 31, 2022 | Three months ended Dec. 31, 2021 | Nine months ended Dec. 31, 2022 | Nine months ended Dec. 31, 2021 |
|---|---|---|---|---|
| Revenue | $332 | $142 | $745 | $275 |
| Gross profit | $102 | $62 | $379 | $126 |
| Gross margin | 31% | 44% | 51% | 46% |
| Operating loss | $(2,278) | $(2,385) | $(7,532) | $(8,927) |
| Net loss | $(2,249) | $(2,381) | $(7,476) | $(8,513) |
| Basic and diluted loss per share | $(0.04) | $(0.05) | $(0.14) | $(0.18) |
- For the quarter, revenue grew 134%, while gross margin declined from 44% to 31%, reflecting product input costs and lower-margin Infrastructure revenue. SG&A fell 24% to $1.574 million, but R&D increased 114% to $806,000 as IGC-AD1 trials and TGR-63 studies progressed.
- For the nine-month period, revenue increased 171%. Life Sciences contributed $686,000 (92%) and Infrastructure $59,000. White-label services were $352,000, versus $22,000 in the prior-year period. SG&A declined 38% to $4.943 million, while R&D rose 171% to $2.968 million.
- Cash and cash equivalents were $4.945 million at Dec. 31, 2022, down from $10.460 million at March 31, 2022. Working capital was $7.998 million, down from $12.670 million. Current assets were $9.354 million and current liabilities $1.356 million.
- Nine-month operating cash outflow was $5.530 million, versus $6.575 million a year earlier. Investing activities provided $7,000; financing provided $101,000, compared with $4.143 million in the prior-year period. The resulting net cash decrease was $5.515 million.
- Total liabilities were $1.753 million, including $141,000 of long-term loans and $371,000 of operating lease liabilities. The company reported no material long-term debt other than disclosed obligations.
Material changes, outlook and risks
- The nine-month net loss narrowed by $1.037 million. Lower SG&A contributed, while higher R&D spending offset some improvement. Prior-year other income included $430,000 of PPP loan forgiveness; other income was $56,000 in the current period versus $451,000 previously.
- The company wrote off approximately $110,000 of inventory during the nine months, recorded in SG&A. It sold a Puerto Rico property for net proceeds of approximately $485,000 and recorded approximately $5,000 profit. Stock-based compensation and related expenses were $2.260 million for the nine months.
- IGC-AD1’s Phase 2 trial had started at U.S. and Canadian sites, with a planned enrollment of 146 participants. Management planned to add additional sites. The company expects R&D expense to rise as trials and TGR-63 development advance; trial outcomes, timing, regulatory approval and commercialization remain uncertain.
- Management said existing cash, short-term investments and liquidity arrangements were expected to support near-term operating and other needs, but the MD&A text is truncated after “over the short,” so the duration of that assessment is unclear. The company expects to seek capital for trials and may use its shelf registration or ATM offering; future equity financing could dilute shareholders. Management also cited potential non-dilutive funding, with no assurance of success.
- Key risks include clinical-trial execution and results, FDA and other regulatory approvals, commercialization of hemp-based products, intellectual-property protection, inflationary pressures, foreign-currency movements and possible COVID-19 effects. The filing describes ongoing Apogee-related litigation; the company denies liability and intends to defend the claims. No material subsequent events were reported.
Important facts for investors to verify
- Cash runway and financing needs, particularly given $5.530 million of operating cash use over nine months and the decline in cash balances.
- Clinical-trial enrollment, site expansion, timing and results for IGC-AD1, and progress and funding requirements for TGR-63.
- Whether increased revenue and white-label sales can be sustained and whether gross margins recover from the quarter’s 31% level.
- Potential dilution from ATM or other equity financing, outstanding restricted stock units and options, and future stock-based compensation.
- Collection prospects for $751,000 of vendor claims receivable, which management said could be challenging within 12 months, and resolution of the Apogee litigation.